These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. [Comparison of urokinase and tissue-type plasminogen activator in transcatheter arterial fibrinolysis]. Vignali C; Cioni R; Mascalchi M; Russo R; Palla A; Lencioni R; Napoli V; Bartolozzi C Radiol Med; 1994; 88(1-2):93-9. PubMed ID: 8066262 [TBL] [Abstract][Full Text] [Related]
36. Safety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion: a comprehensive compilation of published work. Ouriel K; Kandarpa K J Endovasc Ther; 2004 Aug; 11(4):436-46. PubMed ID: 15298504 [TBL] [Abstract][Full Text] [Related]
37. [The administration of thrombolytic agents in peripheral vascular occlusion]. Buth J Ned Tijdschr Geneeskd; 1988 Sep; 132(39):1785-9. PubMed ID: 3054574 [No Abstract] [Full Text] [Related]
39. Streptokinase-A Drug for Thrombolytic Therapy: A Patent Review. Kunamneni A; Durvasula R Recent Adv Cardiovasc Drug Discov; 2014; 9(2):106-21. PubMed ID: 26497671 [TBL] [Abstract][Full Text] [Related]
40. Failure of thrombolytic therapy in four children with extensive thromboses. Ryan CA; Andrew M Am J Dis Child; 1992 Feb; 146(2):187-93. PubMed ID: 1733148 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]